
1. antimicrob agents chemother. 2019 sep 23;63(10). pii: e00538-19. doi:
10.1128/aac.00538-19. print 2019 oct.

cyp2d6 polymorphisms safety gametocytocidal activity single-dose
primaquine plasmodium falciparum.

pett h(#)(1)(2), bradley j(#)(3), okebe j(4), dicko a(5), tiono ab(6), gonçalves 
bp(7), stone w(7), chen i(8), lanke k(1), neuvonen m(2)(9), mustaniemi al(10),
eziefula ac(7)(11), gosling r(8), d'alessandro u(4), drakeley c(7), niemi
m(2)(9), bousema t(12)(7).

author information: 
(1)radboud institute health sciences, radboud university medical center,
nijmegen, netherlands.
(2)department clinical pharmacology, university helsinki helsinki
university hospital, helsinki, finland.
(3)mrc tropical epidemiology group, london school hygiene tropical
medicine, london, united kingdom.
(4)medical research council unit gambia london school hygiene and
tropical medicine, banjul, gambia.
(5)malaria research training centre, faculty pharmacy faculty of
medicine dentistry, university science, techniques technologies of
bamako, bamako, mali.
(6)public health department, centre national de recherche et de formation sur le 
paludisme, ouagadougou, burkina faso.
(7)department immunology infection, london school hygiene tropical 
medicine, london, united kingdom.
(8)malaria elimination initiative, global health group, university california,
san francisco, san francisco, california, usa.
(9)individualized drug therapy research program, faculty medicine, university 
of helsinki, helsinki, finland.
(10)department forensic medicine, university helsinki, helsinki, finland.
(11)brighton sussex centre global health research, brighton sussex
medical school, university sussex, brighton, united kingdom.
(12)radboud institute health sciences, radboud university medical center,
nijmegen, netherlands teun.bousema@radboudumc.nl.
(#)contributed equally

single-dose primaquine (pq) clears mature gametocytes reduces the
transmission plasmodium falciparum artemisinin combination therapy.
genetic variation cyp2d6, gene producing drug-metabolizing enzyme
cytochrome p450 2d6 (cyp2d6), influences plasma concentrations pq its
metabolites associated pq treatment failure plasmodium vivax
malaria. using blood saliva samples varying quantity quality 8
clinical trials across africa (n = 1,076), able genotype cyp2d6 for
774 samples (72%). determined whether genetic variation cyp2d6 has
implications pq efficacy individuals gametocytes time pq
administration (n = 554) safety glucose-6-phosphate dehydrogenase
(g6pd)-deficient individuals treated pq (n = 110). individuals a
genetically inferred cyp2d6 poor/intermediate metabolizer status higher
gametocyte prevalence day 7 10 pq an
extensive/ultrarapid cyp2d6 metabolizer status (odds ratio [or] = 1.79 [95%
confidence interval {ci}, 1.10, 2.90]; p = 0.018). mean minimum hemoglobin
concentrations follow-up g6pd-deficient individuals 11.8 g/dl for
cyp2d6 extensive/ultrarapid metabolizers 12.1 g/dl cyp2d6
poor/intermediate metabolizers (p = 0. 803). cyp2d6 genetically inferred
metabolizer status also associated anemia following pq treatment
(p = 0.331). conclude cyp2d6 poor/intermediate metabolizer status may 
associated prolonged gametocyte carriage treatment with
single-low-dose pq treatment safety.

copyright © 2019 pett et al.

doi: 10.1128/aac.00538-19 
pmcid: pmc6761544
pmid: 31383656  [indexed medline]

